153 related articles for article (PubMed ID: 12873990)
21. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
[TBL] [Abstract][Full Text] [Related]
22. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis.
Demunter A; Ahmadian MR; Libbrecht L; Stas M; Baens M; Scheffzek K; Degreef H; De Wolf-Peeters C; van Den Oord JJ
Cancer Res; 2001 Jun; 61(12):4916-22. PubMed ID: 11406571
[TBL] [Abstract][Full Text] [Related]
23. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
24. Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Pavey S; Johansson P; Packer L; Taylor J; Stark M; Pollock PM; Walker GJ; Boyle GM; Harper U; Cozzi SJ; Hansen K; Yudt L; Schmidt C; Hersey P; Ellem KA; O'Rourke MG; Parsons PG; Meltzer P; Ringnér M; Hayward NK
Oncogene; 2004 May; 23(23):4060-7. PubMed ID: 15048078
[TBL] [Abstract][Full Text] [Related]
25. BRAF mutations in papillary carcinomas of the thyroid.
Fukushima T; Suzuki S; Mashiko M; Ohtake T; Endo Y; Takebayashi Y; Sekikawa K; Hagiwara K; Takenoshita S
Oncogene; 2003 Sep; 22(41):6455-7. PubMed ID: 14508525
[TBL] [Abstract][Full Text] [Related]
26. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
[TBL] [Abstract][Full Text] [Related]
27. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
[TBL] [Abstract][Full Text] [Related]
28. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Lee JH; Choi JW; Kim YS
Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
[TBL] [Abstract][Full Text] [Related]
29. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
30. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
[TBL] [Abstract][Full Text] [Related]
31. The RAS-BRAF kinase pathway is not involved in uveal melanoma.
Kiliç E; Brüggenwirth HT; Verbiest MM; Zwarthoff EC; Mooy NM; Luyten GP; de Klein A
Melanoma Res; 2004 Jun; 14(3):203-5. PubMed ID: 15179189
[TBL] [Abstract][Full Text] [Related]
32. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
[TBL] [Abstract][Full Text] [Related]
33. Absence of mutations of the BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses).
Panagopoulos I; Mertens F; Isaksson M; Mandahl N
Cancer Genet Cytogenet; 2005 Jan; 156(1):74-6. PubMed ID: 15588860
[TBL] [Abstract][Full Text] [Related]
34. Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines.
Melnikova VO; Bolshakov SV; Walker C; Ananthaswamy HN
Oncogene; 2004 Mar; 23(13):2347-56. PubMed ID: 14743208
[TBL] [Abstract][Full Text] [Related]
35. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
36. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
Ugurel S; Thirumaran RK; Bloethner S; Gast A; Sucker A; Mueller-Berghaus J; Rittgen W; Hemminki K; Becker JC; Kumar R; Schadendorf D
PLoS One; 2007 Feb; 2(2):e236. PubMed ID: 17311103
[TBL] [Abstract][Full Text] [Related]
37. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
[TBL] [Abstract][Full Text] [Related]
38. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Tanami H; Imoto I; Hirasawa A; Yuki Y; Sonoda I; Inoue J; Yasui K; Misawa-Furihata A; Kawakami Y; Inazawa J
Oncogene; 2004 Nov; 23(54):8796-804. PubMed ID: 15467732
[TBL] [Abstract][Full Text] [Related]
39. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
40. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]